FLT3 and acute myeloid leukemia: Furthermore, preliminary results on the discontinuation of maintenance after 2 years of treatment confirm both the persistence of long-term remission and possibility to revert MRD positivity through resumption of the drug: sorafenib contributes to sustained long-lasting remissions of FLT3-ITD+ AML after allogeneic HCT.